BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38524109)

  • 21. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
    Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical correlation of cervical cancer screening using Pap smear test.
    Sharif YH
    J Popul Ther Clin Pharmacol; 2022; 29(1):e1-e8. PubMed ID: 35686892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amplification of specific chromosomal regions assessed by fluorescent in situ hybridization on Pap smears to be added as screening tool for identifying women at risk of progressing to cervical cancer.
    Upendram P; Sahni S; Mohiuddin K; Poornima S; Gourishankar B; Kumar Vattam K; Boddala P; Jayashankar E; Mohiuddin S; Kamineni V; Mohan V; Houldsworth J; Hasan Q
    Tumour Biol; 2017 Oct; 39(10):1010428317698363. PubMed ID: 28990460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
    Syrjänen K; Naud P; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Matos J; Gontijo R; Sarian L; Braganca J; Arlindo FC; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S
    Anticancer Res; 2005; 25(5):3469-80. PubMed ID: 16101165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Practice Guidelines on the Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention in Saudi Arabia.
    Al-Mandeel HM; Sagr E; Sait K; Latifah HM; Al-Obaid A; Al-Badawi IA; Alkushi AO; Salem H; Massoudi NS; Schunemann H; Mustafa RA; Brignardello-Petersen R
    Ann Saudi Med; 2016; 36(5):313-320. PubMed ID: 27710981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
    Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
    BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.
    Longatto-Filho A; Naud P; Derchain SF; Roteli-Martins C; Tatti S; Hammes LS; Sarian LO; Eržen M; Branca M; de Matos JC; Gontijo R; Maeda MY; Lima T; Costa S; Syrjänen S; Syrjänen K
    Virchows Arch; 2012 Jun; 460(6):577-85. PubMed ID: 22562132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.
    Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visual inspection with acetic acid for cervical cancer screening outside of low-resource settings.
    Jeronimo J; Morales O; Horna J; Pariona J; Manrique J; Rubiños J; Takahashi R
    Rev Panam Salud Publica; 2005 Jan; 17(1):1-5. PubMed ID: 15720875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.
    Flores Y; Shah K; Lazcano E; Hernández M; Bishai D; Ferris DG; Lörincz A; Hernández P; Salmerón J;
    Salud Publica Mex; 2002; 44(4):335-44. PubMed ID: 12216521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reproducibility of cervical intraepithelial neoplasia diagnosis on histological review of cervical punch biopsies from a visual inspection with acetic acid and HPV detection-based screening program.
    Mittal S; Ghosh I; Banerjee D; Singh P; Biswas J; Nijhawan R; Srinivasan R; Ray C; Basu P
    Int J Gynaecol Obstet; 2014 Sep; 126(3):227-31. PubMed ID: 24947603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aided visual inspection with acetic acid (VIA) and HPV detection as optional screening tools for cervical cancer and its precursor lesions.
    Bragança JF; Derchain SF; Sarian LO; Messias da Silva SM; Labatte S; Zeferino LC
    Clin Exp Obstet Gynecol; 2005; 32(4):225-9. PubMed ID: 16440819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of careHPV for detecting high-grade cervical intraepithelial neoplasia among women living with HIV-1 in Burkina Faso and South Africa: HARP study.
    Segondy M; Kelly H; Magooa MP; Djigma F; Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Michelow P; Doutre S; Clavero O; Chikandiwa A; Sawadogo B; Didelot MN; Costes V; Méda N; Delany-Moretlwe S; Mayaud P
    Br J Cancer; 2016 Aug; 115(4):425-30. PubMed ID: 27434037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.